Dismod 500

Dismod 500

- Pharmacodynamic properties:
  Etamsylate is a synthetic antihaemorrhagic and angioprotective 
  drug acting on the first step of haemostasis (endothelium-platelet
  interaction). By improving platelet adhesiveness and restoring 
  capillary resistance, it is able to reduce bleeding time and blood 
  losses.
  Etamsylate has no vasoconstrictor action, it does not influence
  fibrinolysis nor modify the plasma coagulation factors.
- Pharmacokinetic properties:
- Etamsylate is slowly absorbed from the gastrointestinal tract. After 
  oral administration of 500mg of etamsylate, its maximum plasma
  level,i.e. 15 μg/ml, is reached at 4 h, but bioavailability is not  
  known. The binding rate to plasma proteins is about 95%. Plasma
  half-life is about 3.7 h. About 72% of the administered dose are 
 excreted in the first 24 h-in urine; the molecule is excreted
  unchanged.

- Each tablet of Dismod®  contains: 
  Etamsylate                        500 mg. 

- Dismod® is contraindicated in: 
- Acute porphyria.
- is not intended for administration for children.
- Hypersensitivity to the active substance or to any of the excipients.
- Bronchial asthma, proven hypersesnitivity to sulphites.

- No interaction is known up to now

Pregnancy category C:
- Dismod® should not be administered during the first trimester of 
  pregnancy, whereas during the second and third trimester, it should
  be administered only if the expected therapeutic benefit is judged as
  superior to the potential risk for the foetus.
- lactation during treatment is not advisable or, if lactation is to
  continue, the treatment must be stopped.

- Rare: gastralgia, nausea, headache, skin rash. In most cases, these 
  symptoms disappear spontaneously. If they persist, the dosage 
  should be reduced or the treatment withdrawn.
- Dismod® tablets contains sulphite as antioxidant that may cause 
  allergic reactions, nausea and diarrhea in susceptible patients. The
  allergic reactions may lead to anaphylactic shock and cause
  life-threatening asthma attacks.
  Hypersensitivity towards sulphite is observed more frequently in
  asthmatics than in non- asthmatics.
- In case of hypersensitivity reactions, Dismod® tablets must be
  stopped.
- this include any possible side effect not listed in this leaflet.
  you can report side effect directly via the:
  http\\www.modernpharmaya.com\adrs.pdf and send to us on 
  adrs@modernpharmaya.com 

- liver and kidney function disorder which doctor decide taken the
  Dismod®.
- if no improvment of Dismod® tell your doctor immediatly 
- If  Dismod® is administered for a reduction of excessive and/or
  prolonged menstrual haemorrhages, and no improvement is 
  observed, possible pathological causes should be looked for and
  excluded.

Overdosage:
- No case of overdose has been reported. In case of overdosage, a 
  symptomatic treatment should be initiated.

- Dismod® pack of 2 blisters , Blister of 7 tablets.

- Store at temperture below 25° C.
- protected from light.